Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed,
and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government
operating status and resumption of normal operations can be found at opm.gov.
Rate of 7-day Point Prevalence Abstinence at the End of the Relapse Prevention Phase (Study Week 53) in the Extended Duration Pharmacotherapy Group vs. the Placebo Group
Safety and Tolerability of Extended Duration Pharmacotherapy When Added to Antipsychotic Medications in Schizophrenia Patients Who Have Recently Quit Smoking as Assessed by the Brief Psychiatric Rating Scale
Effect of Treatment With Varenicline Versus Placebo on Health-related Quality of Life Indices in Recently Abstinent Smokers With Schizophrenia or Bipolar Disorder as Measured by the 12-Item Short Form Health Survey (SF-12)
18 Years to 70 Years (Adult, Senior)
PHRC# 2007-P-002221 R01DA021245
February 22, 2008
December 21, 2017
May 21, 2015
University of Alabama Psychology Clinic Birmingham, Alabama, United States
Centerstone Research Institute Bloomington, Indiana, United States
Massachusetts General Hospital Boston, Massachusetts, United States
(and 7 more...)
† Study has passed its completion date and status has not been verified in more than two years.